Gambia

Reimbursed Care Access

The Gambia regulates psychoactive substances under its Drug Control Act and enforces control primarily through the Drug Law Enforcement Agency (DLEAG). Traditional and research uses of classic psychedelics are not part of the national, reimbursed healthcare offering; ketamine is the only listed/commonly used drug among these compounds for routine medical anaesthesia in public and private hospitals, while licensed/marketed products derived from novel psychedelic drug-development (e.g., esketamine/Spravato) have no public record of marketing approval or reimbursement. National health financing is in transition toward a National Health Insurance Scheme, but out-of-pocket payment remains common and reimbursement for specialty psychiatric medicines is limited. [https://www.dleag-gambia.org/en/article/drug-laws|DLEAG — Drug Laws] [http://www.mca.gm/|Medicines Control Agency (The Gambia)] [https://policies.gov.gm/f/561989a6-7ff0-11ef-b086-029254d29bb1|Gambia Health Financing Strategy 2019–2024]